Aurora Cannabis Inc. (ACB:CA) — TD Securities maintained its Buy rating with a C$8.00 price target. Aurora reported 17% year-over-year growth in international medical cannabis revenue in its fiscal 2027 first quarter, supported by its focus on regulated medical markets. Looking ahead, investors will be watching whether international expansion produces sustainable margins and cash flow. Regulatory changes, pricing pressure and operating discipline remain key risks to the growth outlook.
STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.